Qingdao Haier Biomedical Co.,Ltd (SHA:688139)
33.80
+2.21 (7.00%)
At close: Oct 23, 2026
SHA:688139 Revenue
Qingdao Haier Biomedical Co.,Ltd had revenue of 667.49M CNY in the quarter ending September 30, 2026, with 18.00% growth. This brings the company's total for the last twelve months to 2.53B, up 11.86% year-over-year. In the year 2025, Qingdao Haier Biomedical Co.,Ltd had annual revenue of 2.33B with 1.96% growth. That makes Qingdao Haier Biomedical Co.,Ltd the 12,905th largest company in the world by revenue and 2,237th in China.
Revenue (ttm)
2.53B
Revenue Growth
+11.86%
P/S Ratio
4.16
Revenue / Employee
859.58K
Employees
2,887
Market Cap
10.54B
Revenue by Geography
- Mainland China 1.48B 63.6%
- Others 848.27M 36.4%
Fiscal year ended Dec 31, 2025 See the full SHA:688139 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.33B | 44.84M | 1.96% |
| Dec 31, 2024 | 2.28B | 2.94M | 0.13% |
| Dec 31, 2023 | 2.28B | -583.15M | -20.36% |
| Dec 31, 2022 | 2.86B | 738.18M | 34.72% |
| Dec 31, 2021 | 2.13B | 723.83M | 51.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinocare | 4.93B |
| Cofoe Medical Technology | 3.96B |
| Shandong Weigao Blood Purification Products | 3.76B |
| SonoScape Medical | 2.40B |
| Jafron Biomedical | 1.91B |
| MeHow Innovative | 1.71B |
| Shandong Weigao Orthopaedic Device | 1.49B |
| Shanghai MicroPort Endovascular MedTech | 1.43B |